Immunovaccine Inc. is developing immune therapies for cancer using the company’s DepoVaxTM vaccine technology. DepoVax is a patented formulation provides controlled and prolonged exposure of antigens and adjuvants to the immune system, resulting in a strong, specific and sustained immune response. Immunovaccine’s translational research team is focused on improving responses in advanced cancers by combining […]
Read More